- Home
- QLYS vs IMNM Comparison
QLYS vs IMNM Comparison
Compare QLYS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QLYS | IMNM |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QLYS | IMNM |
|---|---|---|
| Price | $98.75 | $20.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $137.46 | $32.80 |
| AVG Volume (30 Days) | 840.5K | ★ 935.4K |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.99 | ★ 51.40 |
| EPS | ★ 5.44 | N/A |
| Revenue | ★ $321,607,000.00 | $6,941,000.00 |
| Revenue This Year | $9.96 | $18.41 |
| Revenue Next Year | $7.15 | $863.23 |
| P/E Ratio | $18.29 | ★ N/A |
| Revenue Growth | ★ 15.32 | N/A |
| 52 Week Low | $85.14 | $5.15 |
| 52 Week High | $155.47 | $27.65 |
Technical Indicators
Market Signals| Indicator | QLYS | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 37.69 |
| Support Level | $85.14 | $18.98 |
| Resistance Level | $136.70 | $22.57 |
| Average True Range (ATR) | 4.60 | 1.05 |
| MACD | 1.52 | -0.21 |
| Stochastic Oscillator | 69.01 | 8.12 |
Price Performance
Historical ComparisonAbout QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.